<
Difference between revisions of "Chronic Diseases:Information"
From GlycoNet Forum
(Created page with "[public] {{DISPLAYTITLE:Chronic Diseases: Developing new therapies for a variety of chronic diseases }} For decades we have known that an enzymatic process called glycosylatio...") |
|||
| Line 1: | Line 1: | ||
[public] | [public] | ||
| − | {{DISPLAYTITLE:Chronic Diseases: Developing | + | {{DISPLAYTITLE:Chronic Diseases: Developing novel treatments to rare genetic diseases }} |
| − | + | Glycomics presents an opportunity to develop novel treatments for rare genetic diseases that arise from deficiencies in sugar metabolism, such as Gaucher’s disease and Fabyr’s disease. Understanding the biochemical and molecular basis of single gene disorders has led to therapeutic strategies for rare diseases and a realization that development of many common disorders involves altered molecular pathways identified in many rare diseases. Developing therapies for rare diseases thus potentially impacts common disorders. | |
[/public] | [/public] | ||
Latest revision as of 18:55, 5 August 2015
Glycomics presents an opportunity to develop novel treatments for rare genetic diseases that arise from deficiencies in sugar metabolism, such as Gaucher’s disease and Fabyr’s disease. Understanding the biochemical and molecular basis of single gene disorders has led to therapeutic strategies for rare diseases and a realization that development of many common disorders involves altered molecular pathways identified in many rare diseases. Developing therapies for rare diseases thus potentially impacts common disorders.
|
